ROS1 and non-small cell lung carcinoma: Rihawi et al. noted one case of NSCLC with a ROS1–MET co-mutation, and MET inhibitor capmatinib treatment failed, followed by crizotinib treatment, and a PFS of up to 11 months (Rihawi et al., 2018).